David A. Siegel Merus N.V. Call Options Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MRUS
# of Institutions
164Shares Held
47.9MCall Options Held
123KPut Options Held
293K-
Commodore Capital LP New York, NY4.36MShares$258 Million16.96% of portfolio
-
Rtw Investments, LP New York, NY4.11MShares$243 Million2.97% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY2.65MShares$157 Million2.46% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA2.25MShares$133 Million0.24% of portfolio
-
Samlyn Capital, LLC New York, NY2.08MShares$123 Million1.66% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.71B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...